ReviewAntioxidants (Basel, Switzerland)2026
Plant-Derived Vesicle-like Nanoparticles for Cancer Therapy: From Drug Delivery to Combined Immunotherapy.
Review in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Plant-derived vesicle-like nanoparticles (PDVLNs) are a unique class of natural nanomaterials secreted by plant cells. Endowed with intrinsic biocompatibility, minimal immunogenicity, and a molecular cargo rich in lipids, proteins, nucleic acids, and unique metabolites, PDVLNs exhibit significant potential in cancer treatment. With the development of diverse engineering strategies and loading methods, PDVLNs have been well established as an ideal drug delivery platform for transporting a broad spectrum of anti-cancer agents, including nucleic acids, proteins, and conventional chemotherapeutics. Notably, accumulating evidence highlights PDVLNs as a novel nanoplatform for combined cancer immunotherapy. This review systematically summarizes the biogenesis, isolation methods, compositions, and anti-tumor activity and mechanisms of PDVLNs, emphasizing their synergistic applications with cancer immunotherapies. Finally, it also discusses the challenges related to production optimization, delivery efficiency, safety issues, and clinical translation facing current research. In the future, as mechanistic insights deepen and nanotechnology advances, PDVLNs are poised to become next-generation immunomodulatory nanoplatforms for enhanced cancer immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.